PKA regulatory subunits mediate synergy among conserved G-protein-coupled receptor cascades by Stefan, Eduard et al.
ARTICLE
1 NATURE COMMUNICATIONS   |   2:598   |     DOI:   10.1038/ncomms1605    |   www.nature.com/naturecommunications
© 2011 Macmillan Publishers Limited. All rights reserved.
Received 22 Sep 2011     |     Accepted 18 Nov 2011     |     Published 20 Dec 2011   DOI:  10.1038/ncomms1605 
 G-protein-coupled receptors sense extracellular chemical or physical stimuli and transmit these 
signals to distinct trimeric G-proteins. Activated G  α  -proteins route signals to interconnected 
effector cascades, thus regulating thresholds, amplitudes and durations of signalling. G  α s-  or 
G  α  i-coupled receptor cascades are mechanistically conserved and mediate many sensory 
processes, including synaptic transmission, cell proliferation and chemotaxis. Here we show 
that a central, conserved component of G  α  s-coupled receptor cascades, the regulatory subunit 
type-II (RII) of protein kinase A undergoes adenosine 3  ′ -5 ′  -cyclic monophosphate (cAMP)-
dependent binding to G  α  i. Stimulation of a mammalian G  α  i-coupled receptor and concomitant 
cAMP-RII binding to G  α  i, augments the sensitivity, amplitude and duration of G  α i: β  γ   activity 
and downstream mitogen-activated protein kinase signalling, independent of protein kinase 
A kinase activity. The mechanism is conserved in budding yeast, causing nutrient-dependent 
modulation of a pheromone response. These ﬁ  ndings suggest a direct mechanism by which 
coincident activation of G  α  s-coupled receptors controls the precision of adaptive responses of 
activated G  α i-coupled  receptor  cascades.          
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 C
ells use versatile molecular signalling circuits to integrate and 
distinguish the quantity of extracellular signalling cues and to 
implement appropriate physiological responses. Cell surface 
plasma membrane receptors sense and the associated signal trans-
ducer guides the signal to adaptive intracellular eff  ector circuits  1,2 . 
Adaptation is an essential feature of life, observed in a range of phe-
nomena, including buff  ering of genetic variation in populations for the 
maintainance of homeostasis against perturbations in organisms and 
individual cells  3,4  . Signal transduction pathways oft  en show adapta-
tion to input signals, notably, allowing for sensing of chemical or light 
gradients over a wide range of concentrations or intensities as well as 
for polarization and direction sensing in chemotaxis  5 – 8 .  Molecular 
mechanisms for adaptation are attributed to integral negative feed-
back circuits  8  that robustly convey the information sensed by cell sur-
face receptors to accomplish the proper physiological response  2,9,10 . 
A key question about signalling is how sensitivities, amplitudes and 
durations of adaptive responses are controlled; particularly when 
coincident, potentially contradictory signals are received by a cell. 
  An important class of signalling pathways in which to explore 
coincident signalling is among those coupled to the largest family 
of cell surface receptors, the G-protein-coupled receptor (GPCR) 
superfamily that are implicated in a large number of cellular pro cesses, 
from light and hormone sensing to chemotaxis and memory consoli-
dation  2,7,11 – 14  . Heterotrimeric G-proteins function as transducers 
of extracellular signals detected by GPCRs to intracellular eff  ectors  2 . 
Th  e adenosine 3  ′ -5 ′  -cyclic monophosphate (cAMP)-dependent 
protein kinase A (PKA) is the main and evolutionarily conserved 
cAMP eff  ector of signal transduction in response to an assortment of 
hormones and physical stimuli  11,15 – 17  . In the canonical descrip-
tion of GPCR signalling, G-protein   α s  (G α s)-coupled  receptors 
activate adenylate cyclase (AC)-mediated synthesis of the second 
messenger cAMP, which in turn binds to PKA regulatory subunits 
(R), inducing dissociation of tetrameric R  2 :PKAc 2   (PKAc    =    PKA 
catalytic subunit) holoenzymes, resulting in active PKAc subunits 
( Fig.  1a ) 15,17,18  . In contrast to the AC   ‘  stimulatory  ’   G-protein   α s 
(G  α  s)-coupled pathway, G-protein   α i  (G α i)-coupled  receptors 
 ‘ inhibit ’   AC  activities 19  . In addition various G-protein-depend-
ent (for example,   via   G α i: β  γ  ) and G-protein-independent path-
ways link GPCRs to mitogen-activated protein kinase (MAPK) 
signalling cascades (  Fig. 1a  )  20 – 23 .  Th   e main cellular eff  ectors of free 
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             Figure  1     |        PKA  regulatory  subunits  form  cAMP-dependent  complexes  with  G  i  isoforms. (  a  ) Schematic representation of GPCR cascades linked to 
cAMP turnover and MAPK activation. G  α  -proteins modulate AC activities. Activation is shown by the arrows and inhibition is shown by T-bars. Blue arrow 
indicates novel connection of R subunits to G-protein-  α  i. Dotted lines indicate activated kinases (PKA subunits: R, PKAc; P stands for phosphorylated 
MAP kinase Erk1  /  2). (  b  ) Fluorometric analysis of transiently transfected COS7 cells co-expressing PKA subunits as bait tagged with Venus-YFP PCA 
fragment[2] (RII  β  -F[2], PKAc-F[2]) with indicated prey proteins fused to F[1]. Fluorescence images of HEK293 cells co-expressing indicated protein pairs. 
Scale bar, 10       μ m.  ( c  ) Spotted peptides (25 mers, 20 aa overlap) of RII  β   (aa1-25 spotted on A1, aa6-30 on A2 and so on) were overlaid with recombinant 
GST-G  α  i3 followed by immunoblotting (IB). (  d  ) Bar graph illustrates the densitometric quantiﬁ  cation of the average of   n     =    3  dot  blot  experiments  as  shown 
in   c  . Red bars point to the sequence of the only binding interface of Reg:G  α  i (red box; referred as   ‘  Reggai peptide  ’  ) in the illustrated modular structure of 
RII  β .  ( e  ) Under basal conditions and following forskolin treatment (15     min, 100       μ  M) of HEK293 cells, we precipitated endogenously expressed RII  α   with 
GST-G  α  i3. Total RII  α   and GST-G  α  i3 are constant, but the quantity of co-precipitated GST-G  α i3:RII α   complexes increases following forskolin treatment. 
Fold enrichment of RII  α   upon forskolin-mediated cAMP elevation is shown (normalized to levels of GST fusion proteins,        ±    s.e.m.  of   n     =    3;  pm,  plasma 
membrane). (  f  ) cAMP precipitation of endogenously expressed PKA complexes using 8-AHA-cAMP or Rp-8-AHA-cAMP immobilized to agarose resin 
from total brain lysates of mice. In the negative control experiment we added excess of cAMP (5     mM) to the brain lysates to mask the cAMP-binding sites 
in the R subunits for precipitation. We have performed densitometric quantiﬁ  cation of RII  β  , PKAc and G  α  i3 (normalized in each case to the most abundant 
protein) from the same immunoblot to compare complex formation and fold enrichment between holoenzyme (Rp-8-AHA-cAMP) and activated R 
complexes (8-AHA-cAMP). Results are presented as means        ±       s.e.m. from three independent experiments for each two independent precipitation. 
Treatments (italic) and readouts (red) are indicated.ARTICLE   
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diff  usible cAMP are PKA R subunits. In addition to the function as 
cAMP sensors and inhibitor of PKAc activity, PKA R subunits bind 
to a variety of A kinase-anchoring proteins (AKAPs), thereby, 
facilitating spatial and temporal compartmentalization of PKA 
signalling  15,24 – 26 . 
  Here we report that PKA regulatory subunits actively participate 
in G  α  i signalling. We describe a novel and conserved mechanism 
through which cAMP-bound R subunits associate specifi  cally with 
G  α  i causing sensitization and increased amplitude and duration in 
response to G  α i-receptor  activation.  
 Results  
  RII subunits form cAMP-dependent complexes with G   i    .     I n   a  
systematic screen for protein:protein interactions in mammalian 
COS7 cells, we identifi  ed novel interactions of PKA regulatory 
subunits type II  β   (RII β  ), but not PKAc subunits, with all the three 
isoforms of G α i (G α i 1,2,3 ) using a  ‘ Venus ’  yellow fl  uorescent protein 
(YFP) protein-fragment complementation assay (PCA;   Fig. 1b  ; 
  Supplementary Fig. S1a  )  27 – 29  . In addition, the phosphoinositide-
dependent kinase 1 (PDK1) interacted with both RII  β   and PKAc, 
suggesting diff   erent modes of binding to PKA for this protein. Further, 
RII  β :RII β   and PDK1:RII  β   complexes were restricted to the cytosol, 
but G  α i:RII β   complexes were localized at the plasma membrane, 
consistent with known localization of G  α  i proteins (  Fig. 1b  ). We 
confi  rmed the RII  β :G α  i3 interaction in glutathione   S -transferase 
(GST) pulldown assays. GST-RII β  binds to endogenously expressed 
G  α  i3 and GST-G  α  i3 binds to purifi  ed RII  β  , suggesting that this 
interaction is direct ( Supplementary Fig. S1b,c ). In a dot blot screen of 
overlapping peptides derived from RII β  (protein accession number: 
EAL24395), we identifi  ed a unique binding motif for G  α i3  within 
the evolutionarily conserved cyclic nucleotide binding domain 
B (CNB-B) and identifi  ed four amino acid (aa) positions required 
for binding to G  α  i3: Asp 308, Phe 313, Phe 314 and Glu 317 
(  Fig. 1c and d  ;   Supplementary Fig. S1d  ). 
  We next asked whether the binding of R subunits to G  α i  could 
be cAMP-dependent and therefore actively mediated by GPCR sig-
nalling. First, in a GST pulldown assay from HEK293 cell lysates 
we confi  rmed the interaction of GST-G  α  i3 and RII  α   under basal 
conditions. However, pretreatment of cells with forskolin, a general 
activator of AC activity augments binding of endogenous cAMP-
bound RII  α   to  GST-G α  i3 (  Fig. 1e  ). Second, we applied total brain 
lysates of mice to 8-AHA-cAMP-coupled (precipitates   ‘  active  ’   
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         Figure  2     |          cAMP-bound  R  subunit  enhances  ligand  triggered  G   i activation and MAP kinase phosphorylation. (  a  ) Endogenous R:G  α i3  complexes 
precipitated from HEK293 cells using 8-AHA-cAMP agarose (representative experiment of   n     =    3).  ( b  ) Conformational changes of trimeric G-proteins 
measured in   δ  OR-HEK293 cells co-expressing the indicated BRET protein reporter pair and PKA subunits following stimulation with forskolin (100    μ M, 
15     min) and then by SNC80 (1       μ M,  3   min;      ±    s.e.m.,   n     =    3  independent  experiments).  ( c  ) cAMP levels measured in   δ  OR-HEK293 cells co-expressing 
the cAMP sensing EPAC BRET reporter and PKA subunits following stimulation with forskolin (50       μ  M, 12     min) and then SNC80 (1       μ M,  6   min;      ±    s.e.m., 
representative experiment,   n     =    3).  Decrease  in  BRET  ratio  (  Δ  -BRET) indicates an increase in cAMP concentration   in vivo  . Inset shows forskolin (       ±    SNC80)-
induced cAMP changes measured with EPAC-BRET in cells overexpressing RII  β   (    ±    s.e.m.).  ( d  ) Effects of combinations of forskolin (100       μ M,  15   min)  and 
SNC80  (1    μ  M, minutes) on Erk1  /  2 phosphorylation in   δ  OR-HEK293 cells; 60     min pretreatment with KT5720 (2       μ  M), representative experiment of   n     =     3 .  
(  e  ) Densitometric quantiﬁ  cation of Erk1  /  2 phosphorylation upon SNC80  /  forskolin treatment,        ±    s.e.m.  from   n     =    3.  Statistical  signiﬁ  cance was assessed 
using a paired Student  ’  s   t -test.  Signiﬁ  cance of individual results were determined at different levels as indicated with     #    and    #  #    (  #   P -values      <    0.05;   #  #  P -values 
       <       0.01). Treatments (italic) and readouts (red) are indicated.   ARTICLE
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R subunits) and Rp-8-AHA-cAMP-coupled (precipitates R:PKAc 
holoenzymes) agarose beads. Endogenous R subunits, bound to 
both types of agarose beads, co-precipitated endogenous G  α i3.  In 
line with the observation from   Figure 1e  , we verifi  ed preferential 
binding of G  α  i3 to endogenous and   ‘  activated  ’   R subunit complexes 
  in vivo   ( Fig.  1f ).  Th  ese results were surprising, suggesting that in 
addition to cAMP binding to R subunits and mediating the disso-
ciation of the R  2 :PKAc 2   holoenzyme, cAMP may mediate the active 
association of R subunit complexes to G  α i  proteins.   
  cAMP-bound R subunits modulate    OR-triggered  G  i  activities   .  
    To examine the potential role of R:G  α  i complexes in GPCR signal-
ling, we used a well-defi  ned model cell, HEK293 cells stably express-
ing the exclusively G  α i-coupled   δ  -opioid receptor (  δ OR) 30 .  First, 
we confi  rmed complex formation of R:G  α  i3 in two independent 
cell lines under basal conditions, in HEK293 cells and in the oste-
osarcoma cell line U2OS, respectively (  Fig. 2a  ;   Supplementary Fig. 
S2a  ). Next we determined how formation of cAMP-triggered R:G  α i 
complexes could eff  ect   δ  OR coupling to and activation of G  α i.  For 
this purpose, we utilized bioluminescence resonance energy transfer 
(BRET)-based assays. Th   e advantage of the fi  rst assay is that it directly 
reports on a known conformational rearrangement of the trimeric 
G  α i: β  γ   complex driven by ligand binding to a GPCR, coupled to the 
G  α  i-protein complex (  Fig. 2b  )  31  . As expected, we observed that the 
  δ  OR agonist SNC80 induced a decrease in BRET between G  α i1  and 
G  γ 2,  refl  ecting activation of the G-protein. However, and interest-
ingly, direct activation of cAMP production by forskolin potentiated 
the G  α i1:G γ  2 conformational rearrangement resulting from recep-
tor activation, suggesting that cAMP-mediated activation of PKA 
enhanced activation of G α i, possibly  via  the formation of the R:G α i1 
complex. Forskolin treatment alone had no eff  ect on the conforma-
tion of the trimeric G-protein complex (  Supplementary Fig. S2b  ). 
Further, overexpression of RII  β   and the BRET sensor, but not of cat-
alytically active PKAc, enhanced both SNC80 and SNC80    +    forskolin 
eff  ects on the G  α  i activation monitored by BRET (  Fig. 2b  ). 
 As activated G α i is known to inhibit AC, we predicted that cAMP 
and R-mediated augmentation of G  α  i activity should potentiate the 
  δ  OR-mediated inhibition of AC and consequently decrease cAMP 
production. We tested this hypothesis using a BRET cAMP reporter 
based on the structure of the cAMP-regulated guanine nucleotide 
exchange factor (Epac) that undergoes conformational changes upon 
binding to cAMP. Th  is assay enables accurate detection of   in vivo  
cAMP levels indicated through a decrease of BRET  32 .  We  observed 
that overexpression of RII β , but not of PKAc, caused a further decrease 
in  cAMP  production  when  cells  were  treated  with  SNC80    +    forskolin 
compared with cells treated with forskolin alone (  Fig. 2c  ). 
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  We next examined the potential function of R:G  α i  complex
formation on receptor-mediated activation of MAPK in mammalian 
cells  20   ( Figs  2 – 4 )  and  budding  yeast 33   (  Figs 5 and 6  ). We used the 
human   δ  OR-HEK293 model for these experiments because they 
have the advantage that under basal condition and upon only For-
skolin or only cAMP analogue treatments, no collateral eff  ects on 
MAP kinase Erk1  /  2 activation are observed. As already known, 
the   δ  OR-selective agonist SNC80 induces a transient increase of 
the  Erk1 / 2  phosphorylation  in   δ  OR-HEK293 cells. Pretreatment 
with forskolin potentiated SNC80-induced Erk1  /  2 phosphorylation 
( Fig. 2d,e ). Th   ese data support the notion that the cAMP-dependent 
R:G  α i complexes increase the sensitivity of this G α i signalling path-
way to   δ  OR activation. Th   e increase in sensitivity is distinct from 
activation through cross-talk in which a MAPK is activated by a 
G  α s-coupled receptor and dependent on PKA catalytic activity  22,34 . 
To exclude the possibility that PKA kinase activity could account 
for this potentiation, we pretreated cells with the PKA inhibitor 
KT5720 (unless noted otherwise, all subsequent experiments were 
carried out in the presence of this kinase activity inhibitor). Th  e 
inhibition of catalytic PKA phosphotransferase activity did not pre-
vent the forskolin-mediated potentiation of the MAPK activation 
(  Fig. 2d  ). We confi  rmed that KT5720 inhibits PKA kinase activity 
under the conditions used in   Figure 3   by monitoring the cAMP 
response element-binding protein (CREB) phosphorylation (acti-
vated independently of G  α i  signalling;   Supplementary  Fig.  S2c,d ).   
  cAMP-RII subunits modulate    OR-triggered  G  i  activities   .     We  
next asked whether cAMP-bound forms of distinct PKA regulatory 
subunits type I (RI) or R type II (RII) increase the sensitivity of G α i-
mediated   δ OR  signalling 15  . We thus directly activated endogenous 
PKA with combinations of membrane permeable cAMP analogues 
that bind selectively to the CNB-A or CNB-B of RI or RII  35,36 .  We 
fi  rst determined the concentration- and time-dependent eff  ects of 
each cAMP analogue on RII:PKAc dissociation in intact cells (using 
a   Renilla   luciferase (  R  luc)-based PKA reporter assay  29 ;   Fig.  3a ; 
  Supplementary Fig. S3  ). Maximally active RI subunit cAMP ana-
logues (8-PIP-cAMP, 2-Cl-8-MA-cAMP) had no eff   ect, but the 
RII subunit-binding analogues (6-MBC-cAMP, Sp-5,6-DCl-
cBIMPS  35,36  ) potentiated the amplitude and duration of SNC80-
induced Erk1  /  2 phosphorylation (  Fig. 3b,c  ;   Supplementary 
Figs S3c,4a  ). Th   ese observed eff  ects occurred through G  α i  signal-
ling as pretreatment of cells with pertussis toxin, which uncou-
ples G  α  i from the receptor, prevented both receptor and cAMP 
analogue-potentiated Erk1  /  2 phosphorylation (  Fig. 3b  ). 
  We next asked whether RII binding to G  α  i may enhance sen-
sitivity of G  α  i-coupled receptor signalling by somehow shift  ing 
G  α  i to its active, GTP-bound state. We used an antibody to selec-
tively precipitate GTP-loaded G  α  i in untreated, SNC80 or SNC80 
plus RII-specifi  c cAMP-analogue-treated   δ  OR-HEK293 cells. By 
immunoblotting (IB) with the isoform selective G  α i3  antibody 
we observed elevated levels of immunoprecipitated GTP-G  α i3, 
following both RII and   δ OR  activation  ( Supplementary  Fig.  S4b ). 
Exclusive treatment with RII-specifi  c cAMP-analogues shows no 
activation of Erk1  /  2 in HEK293 cells (see below,   Fig. 4b  ). Th  ese 
results, together with our observation of enhanced conformation 
change of G  α i: β  γ   complex under the same conditions (  Fig. 2b  ), 
suggest that the active GTP  –  G  α  i complex is favoured when bound 
to cAMP-RII:G  α i  following  G α  i-coupled receptor activation. 
  Our results suggest that preventing cAMP-triggered PKA 
dissociation and hence formation of RII:G  α i  complexes  would 
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 prevent G α i-coupled receptor signal augmentation by cAMP. To test 
this prediction, we used the cAMP analogue Rp-cAMP, an inhibitor 
of PKA holoenzyme dissociation. Pretreatment with Rp-cAMP 
decreased  SNC80    +    RII  subunit  activator  (6-MBC-cAMP,  Sp-5,
6-DCl-cBIMPS)  and  SNC80    +    forskolin-mediated  Erk1 / 2  phos-
phorylation (  Fig. 3d  ) to a similar extent as it prevented PKA 
holo  enzyme dissociation (  Supplementary Fig. S4c,d  ).     
  cAMP-RII:G  α  i complexes modulate ligand sensitivity   .     We   n e x t  
tested whether the induction of cAMP- ‘ activated ’  RII:G α i complexes 
aff  ect receptor:G protein coupling. First, we performed a BRET assay 
that reports directly on G  α  i1 coupling to   δ  OR in response to ago-
nist binding to the GPCR  30,31  . We observed that forskolin potenti-
ated the SNC80-induced increase in BRET between   δ  OR and G  α i1 
(  Fig. 4a  ), which is consistent with the idea that the formation of 
the RII:G  α  i complex potentiates the receptor-mediated activation 
of G  α  i1. Moreover, a dose  –  response of the   δ OR  agonist  SNC80-
mediated ERK1  /  2 phosphorylation following pretreatment with the 
selective PKA phosphotransferase inhibitor KT5720 performed in 
the presence and absence of RII subunit-specifi  c cAMP analogues 
showed a signifi  cant, sevenfold increase in sensitivity of the MAPK 
pathway to stimulation (  Fig. 4b  ). 
  To test whether direct disruption of the RII:G  α  i complex would 
prevent cAMP-dependent sensitization of G  α i  to  receptor  activa-
tion, we created a membrane-permeable peptide competitive antag-
onist of RII:G  α  i binding based on the G  α  i3 binding motif that we 
identifi  ed in RII (  Fig. 1c,d  ). Coding sequence for this peptide was 
fused to that of the membrane-permeant HIV TAT peptide and 
expressed in and purifi  ed from  Escherichia coli  37 . Treatment of cells 
with this peptide (we call Reggai) prevented the potentiation of 
SNC80-mediated Erk1  /  2 phosphorylation by RII subunit-specifi  c 
cAMP analogues (  Fig. 4c  ). A TAT control peptide had no eff  ect. 
Th   ese data highlight that formation of cAMP-dependent RII:G  α i 
complexes are required for the transmission of signal from G  α s-  to 
activated G  α i-cascades.   
  cAMP-RII modulation of G    i is conserved in budding yeast   .  
  Th  e evolutionary conservation of PKA R subunits and notably of 
two critical aa  ’  s for interaction in the Reggai sequence, Asp 308 
and Glu 317 (  Fig. 5b  ;   Supplementary Fig. S1d  ), prompted us to 
evaluate whether the cAMP-bound R subunit-mediated modula-
tion of G  α  i signalling is also conserved in yeast. Th  e  budding  yeast 
  Saccharomyces cerevisiae  (S. cerevisiae)   has homologues of the 
mammalian signalling components for both PKA and MAPK path-
ways downstream of GPCRs. Yeast express the glucose-sensing 
G  α  s-coupled receptor Gpr1 and in the   MAT  a   haploid strain, the 
Ste2 pheromone receptor, which is G  α i-coupled  ( Fig.  5a ) 17,38 .  Th  e 
signalling counterpart to the G  α i: β  γ  -MAPK cascade in   S. cerevisiae  
is activated by the mating pheromone   α -factor  (in   MAT  a   hap-
loid cells), resulting in a distinct morphogenic   ‘  shmoo  ’   response 
(  Figs 5a and 6a,b  )  33 .  We  fi  rst tested for interactions of the single 
G  α  i and G  α  s homologues (Gpa1 and Gpa2) with the single yeast 
PKA R subunit Bcy1, using the Venus YFP PCA and observed 
that Gpa1, but not Gpa2, interacts with Bcy1 in a complex at the 
plasma membrane (  Fig. 5b  ;   Supplementary Fig. S5  ). Th  ese  results 
are consistent with our observations in mammalian cells (  Fig. 1b  ). 
Furthermore, point mutations of homologous Asp 308 and Glu 
317 residues in the Reggai binding motif of Bcy1 decreased the 
interaction of Bcy1 with Gpa1, but did not aff  ect the Bcy1:Bcy1 
or  Bcy1:Tpk2  (Tpk    =    PKAc)  complexes  ( Fig.  5b ;   Supplementary 
Fig. S5  ). Finally, we observed that mammalian RII  β   and G  α i3 
interacted with the yeast R subunit Bcy1 (  Supplementary Fig. S6  ). 
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Th   ese results suggest that the specifi  c R:G  α  i interaction has been 
conserved for at least 1.5 billion years since Metazoa and Fungi 
lineages separated  39 . 
  We next examined the role of Bcy1 on downstream pheromone 
signalling, including activation of the yeast MAPK homologue Fus3 
phosphorylation  and  the   ‘ shmoo ’   response 33   in the presence of the 
trigger for cAMP-production, glucose. We observed an approxi-
mately threefold decrease in sensitivity to   α -factor-induced  Fus3 
phosphorylation  and   ‘ shmoo ’   response  (EC 50   right  shift  ) in an 
isogenic knockout of the   bcy1   gene (  bcy1  Δ   )  ( Fig.  5c   lower  panel, 
 Fig.  6c ).  Th   ese data correlate with the observation that in mamma-
lian cells activation of PKA RII shift  s the EC  50   curve of G  α i-cou-
pled receptor activation to the left   (  Fig. 4b  ). Expression of a Reg-
gai-binding  motif  mutant  of  Bcy1  (    =    Bcy1 * )  expressed  in  the   bcy1  Δ    
strain produced an intermediate decrease in both Fus3 phospho-
rylation (twofold) and also the   ‘  shmoo  ’   response (1.6-fold). Over-
all, the reduced MAP kinase activation and   ‘  shmoo  ’   response in 
yeast resulting in a EC  50   shift   of   α -factor  to  higher  concentration 
indicates that, as in mammalian cells, the yeast R subunit Bcy1 
potentiated the G  α i: β  γ  -mediated MAPK pathway (  Figs 5c and 6  ). 
However, we observed no impact of Bcy1 overexpression on MAPK 
activation and on the shmooing response, suggesting that Bcy1 is 
already highly expressed in yeast and that the pathway is less sensi-
tive to overexpression. Further, consistent with our model, the PKA 
inhibitor KT5720 had no eff  ect on MAPK phosphorylation or the 
shmoo response (  Fig. 5c   lower panel,   Fig. 6c  ). In summary, data 
presented in   Figures 4  –  6   support our argument for an evolutionar-
ily conserved function of R subunits in regulating the sensitivity of 
G  α  i-coupled signalling responses (shift   of EC  50  curves). Application 
of the Reggai peptide in mammalian cells (  Fig. 4c  ) and mutational 
modifi  cation of the same motif in budding yeast R subunits (Bcy1; 
 Figs 5c and 6b,c ) suggests a conserved mechanism for cAMP-bound 
R subunits to modulate G  α i  signalling.    
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 Discussion 
  Over the past 40 years, the canonical view of GPCR cascades regu-
lating cAMP synthesis has placed the PKA R subunit in the role 
of inhibiting PKAc subunit activity  15,16  , and more recently, local-
izing specifi  c signalling complexes to subcellular locations through 
AKAP scaff  olding proteins  24,26  . We now report the discovery that 
cAMP-activated R subunits (functioning as pivotal component 
of G  α  s-coupled receptor cascades) directly bind to and modulate 
G  α  i-coupled receptor signalling (  Fig. 7 ).     In contrast to AKAP bind-
ing   via   the N-terminal docking domain of R subunits, the cAMP-
dependent interaction between RII:G  α  i is mediated by the fl  exible, 
cAMP-binding CNB domain, which is conserved in all organisms, 
except in plants  40 . We describe how this dynamic binary interaction 
provides a simple means to control sensitivity, amplitude and dura-
tion of adaptive signalling responses. 
  We present a detailed molecular description of how activated 
R subunits in yeast and mammalian cells directly control G  α i-
  mediated activation of MAPK responses. In the yeast model, the 
function of the R:G  α  i interaction is clear. Diploid yeast undergoes 
meiosis when starved and haploids mate when nutrients become avail-
able. Glucose, the preferred carbon source of yeast, activates a G  α s-
  coupled receptor and in turn cAMP synthesis and PKA activation. 
It, thus, follows that the modulation of pheromone sensitivity that 
we observe is mediated by R subunit binding to G  α  i and serves to 
sensitize the pheromone response to the fact that the best carbon 
source is available  17 . 
  In mammalian cells, the phosphotransferase-independent 
function of cAMP-bound R subunits reported here will need to 
be understood in the context of known GPCR signalling dynam-
ics  11,12,41 – 43  . First, ACs and GPCRs are themselves targets of 
receptor-activated kinases that control ligand sensitivity and turn-
over and can lead to the activation of distinct G-protein pathways 
(switch from primary G-protein-coupling from G  α s  to  G α i),  as 
observed for human  β  2 -adrenergic receptor activation  19,44 – 46 . Th  is 
is distinct from the mechanism we describe here, in which a con-
stituent of G  α  s-  coupled receptor signalling directly functions on 
G  α  i-coupled receptor signalling. Second, the distinct sites of pro-
tein:protein interaction for AKAPs and G  α i  ( Fig.  1d )  suggest  that 
cAMP-activated RII subunits bring AKAPs into proximity of G  α i 
and its receptor  /  eff  ectors (see also below,   ‘  fi  ft   h ’ ),  further  organiz-
ing compartmentalized signalling complexes  11,22,24,26,44 .  Th  ird, 
recently the mammalian E3 ubiquitin ligase praja2 has been shown 
to target R subunits for degradation in a cAMP-dependent manner 
and thus, could change the degree of sensitivity of G  α i-coupled 
receptor signalling to cAMP-RII modulation of G  α i 26  . Fourth, the 
mechanism we propose creates a negative feedback loop, resulting 
in downregulation of cAMP synthesis   via   G α  i activation and AC 
inhibition. Th   is negative feedback could cause adaptation to G  α i-
coupled signalling itself and also function in concert with other 
feedback circuits to generate cAMP oscillations that couple to 
other, for example, calcium and MAPK oscillators, and may control 
spatial and temporal signalling by PKA  25,47 .  Fift  h, beyond MAPK 
and AC modulation, G  α  i signalling has a broad spectrum of pro-
tein eff  ectors, linking G  α  i to a variety of diverse cellular processes, 
for example, those involved in development and autophagy  46 .  It 
will, thus, be interesting to explore how co-incident modulation of 
G  α  i signalling by G  α  s-generated cAMP-RII may function in these 
pathways. 
 G α  s-mediated control of G  α  i signalling   via   cAMP-RII  could 
be a common mechanism of GPCR-mediated adaptive signalling 
in, as examples, chemotaxis or long-term potentiation in neuronal 
circuits  7,13,14,44,47 – 49  . Chemokine and most neurotransmitter 
receptors mediate adaptive responses and are coupled to G  α i, 
but G  α  s-proteins upstream of its main eff  ector PKA are mostly 
activated by metabolic hormones or autonomic neurotrans-
mitters  50  . In this context, we confi  rmed complex formation of 
  ‘  activated  ’   PKA R subunit complexes and G-protein-  α  i3 in mam-
malian brains under physiological conditions (  Fig. 1f  ). It will be 
interesting to explore how the mechanism we report contributes 
to controlling sensitivity to signals and chemotactic responses 
or neural information processing where a neuron responds to 
one synapse that releases a G  α  i-coupled receptor activator, while 
another simultaneously releases a G  α s-coupled  receptor  binding 
hormone  14,49 . 
  Finally, our results have at least four implications to under-
standing GPCR and PKA pharmacology. First, the fact that G  α i 
signalling sensitivity is increased by G α s-coupled receptor signal-
ling means that the sensitivity of G  α  i-coupled receptor signalling 
processes could be increased by drugs that positively function 
on G  α s-coupled  receptors  ( Fig.  4a,b ) 51  . At the same time, the 
effi   cacy of G  α i-coupled  receptor  agonists / antagonists  could  be 
modifi  ed by treatment with G  α  s-coupled receptor drugs. Th  ere 
are currently compounds in clinical trials for diseases of aberrant 
cell proliferation such as cancers (for example, compounds func-
tioning on G  α  i-coupled CXCR4 and Smoothened receptors), 
and it would be interesting to test whether G  α s-coupled  GPCR 
agonists alter the effi   cacies of these compounds  52 – 54 .  Moreover, 
distinct mechanisms have been proposed to explain how cAMP 
regulates cell-type-specifi  c MAPK signalling, which modulates 
cell growth and proliferation, either positively or negatively  55 . 
For instance, human endocrine tumours have mitogenic MAPK 
activities caused by activating mutations of G  α  i2 (refs     20, 23, 
56  –  58). Finally, cAMP analogues are being used to treat mem-
ory defi   ciencies caused by neurodegenerative diseases  59 .  Th  e 
actions of these compounds will need to be considered in light 
of the mechanism that we have discovered. Th   e Reggai peptide 
we report here may, itself prove a useful lead for development 
of drugs that modulate sensitivity of G  α  i-coupled, for example, 
neurotransmitter receptors.     
 Methods  
  Antibodies   .    Antibodies  used  were   anti-RII β    ( BD  Bioscience ,   # 610626,  1:2000), 
 anti-RII α    ( BD  Bioscience ,   # 612242,  1:2000),   anti-PKAc α    ( BD  Bioscience ,   # 610981  , 
1:2000),   anti-G  α  i3   (  Santa Cruz  ,   #  sc-262, 1:200),   anti-active G  α i  antibody   ( New 
East Biosciences  ,   #  26901, 1 microgram/precipitation),   anti-Erk1 / 2   ( Cell  Signaling , 
 # 9102,  1:2000),   anti-phospho-Erk1 / 2   ( Cell  Signaling ,   # 9101,  1:2000),   anti-CREB  
( Cell  Signaling ,   # 9104,  1:1000),   anti-phospho-Serine133-CREB   ( Cell  Signaling , 
 # 9198,  1:1000),   anti-GFP   ( Roche ,   # 11814460001,  1:2000,   anti-Flag   ( Sigma ,   # F3165, 
1:2000) and   anti-GST   (  Sigma  ,   #  G1160, 1:1000).     
  Construction of plasmids   .     
  Venus YFP PCA expression vectors and fusion constructs   .     Th   e PKA regulatory 
subunit (rat,   RII  β  ) and the PKA catalytic subunit (mouse,   PKAc  α )  were  subcloned 
into the 5  ′  -end to the Venus YFP PCA fragments, referred to here as N-terminal 
fragment (1  –  158 aa; F[1]) and the C-terminal fragment (159  –  239 aa; F[2]) as 
previously described  27 – 29      . To screen for interacting proteins, we generated 
plasmids designed to serve as expression and destination vectors for lambda 
recombinase subcloning of mouse cDNAs harboured in Gateway-ready entry 
vectors (unpublished results). Venus YFP PCA fragments were subcloned into a 
pcDNA 3.1 expression vector with the appropriate Gateway reading frame cassette 
to generate the C- and N-terminal destination vectors for each PCA fragment. 
cDNAs of interest were subcloned into these destination vectors with   LR (lambda 
recombinase) clonase   as recommended by the manufacturer (  Invitrogen Corpora-
tion ).  GST fusion protein constructs. We constructed a fusion protein consisting 
of G  α  i3 and GST to be used in GST pulldown experiments and dot blot analysis. 
Th   e cDNA for   G  α  i3   was  amplifi  ed from   rat heart Marathon-Ready cDNA   
(  BD Biosciences  ) by PCR and cloned into the multiple cloning site of the GST 
expression vector pGEX-5X-1   via Eco RI /  Xho I.  Th   e  GST – RII β   construct was kindly 
provided by E. Klussmann (FMP-Berlin, Free University Berlin). Oligos coding for 
the 15 amino acids of the Reggai peptide were cloned into the multiple cloning site 
of pGEX-4T-2 (  via Eco RI /  Xho I)  fl  anked upstream with the sequences for   GST ,   Tat  
and   Flag   antigenic peptide tag  37  . All GST fusion proteins were expressed in   E. coli  
(strain BL21). Induction, cell lysis and affi   nity purifi  cation of fusion proteins were 
performed as recommended by the supplier of the   pGEX vectors   (  GE Healthcare  ).       
  Fluorometric analysis of Venus-PCA-tagged proteins   .    COS7  cells  grown  in 
12-well plates were co-transfected with the Venus YFP PCA expression vectors 
(pcDNA3.1) coding for prey-F[1] and  /  or bait-F[2] using   FuGENE6 reagent   ARTICLE   
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(  Roche  ). Fluorometric analysis and imaging have been performed as previously 
described  27 – 29  . For localization of protein  –  protein interactions in   S. cerevisiae , 
we utilized the same variants of Venus YFP PCA fragments as described above. 
We co-transformed   MAT    a   (strain BY4741) strains of   S.cerevisiae   with  plasmid 
p413 (for F[1]; ADH promotor) and plasmid p415 (for F[2]; ADH promotor) en-
coding the following Venus YFP PCA fusions (Bcy1-F[1], Bcy1-F[2], Bcy1  *  -F[1], 
Bcy1  *  -F[2], Tpk2-F[1], Gpa1-F[2] and Gpa2-F[2]). Positive clones were selected 
on the synthetic complete media lacking Histidine (His) and Leucine (Leu). Cells 
were grown in low-fl  uorescent media, and images were taken using a   Nikon Eclipse 
TE2000U inverted microscope   (  Nikon  )     with   ×  60 objective and   YFP fi  lter cube   
(41028,   Chroma Technologies  ). Images were captured with a   CoolSnap CCD cam-
era   ( Photometrics )  using   Metamorph  soft   ware   ( Molecular  Devices ).  We  quantifi  ed 
the fl  uorescence intensities from individual cells using the ImageJ soft   ware.   
  SPOT synthesis and overlay experiments   .    Overlapping  peptides,  either  of 
RII  β   or peptides-containing substitutions of conserved amino acids in the Reggai 
sequence, were SPOT synthesized on distinct coordinates of a cellulose membrane. 
Membranes were overlaid with recombinant GST-G  α i3  (10    μ g   ml     −     1   blocking 
buff  er). Interactions were detected with anti-GST and secondary horseradish 
peroxidase antibodies by a procedure identical to IB.     
  cAMP agarose protein precipitation assays   .    HEK293,  U2OS  cells  and  total 
brains of mice were homogenized using a   Potter S   (  B. Braun Biotech International  ) 
with 15 strokes. We clarifi  ed the lysate (13,000     r.p.m., 15     min) and precipitated 
the R-subunit-associated protein complexes with   PKA-selective 8-AHA-cAMP 
agarose and Rp-8-AHA-cAMP agarose resin   (  Biolog  ,   #  D014,   #  M012) for 2     h at 
4       °  C. As negative control experiment we added excess of cAMP (5     mM) to lysates to 
mask the cAMP-binding sites in the R subunits for precipitation. Resin-associated 
proteins were washed four times with lysis buff  er and eluted with Laemmli sample 
buff  er. Equal amount of protein were subjected to polyacrylamide gel electrophore-
sis followed by IB. We performed densitometric quantifi  cation of RII  β ,  PKAc  and 
G  α  i3 (in each case, normalized to the most abundant precipitated protein) from 
the same immunoblot (  n     =    3)  to  compare  complex  formation  and  fold  enrichment 
between holoenzyme (precipitated with Rp-8-AHA-cAMP) and activated R 
complexes (precipitated with 8-AHA-cAMP).   
  Bioluminescence resonance energy transfer measurements   .      δ OR-HEK293 
cells were transiently transfected with G  α  i1 with the   R  luc inserted at aa position 
91 and the ultraviolet-shift  ed GFP variant GFP10 (substitutions: P64L, S147P and 
S202P) fused to the C-terminus of G  γ  2 or the ultraviolet-shift  ed variant GFP2 
(substitution: F64L) fused to the C-terminus of the   δ  OR. In overexpression studies, 
we co-expressed RII  β   or PKAc. For cAMP measurements, we co-expressed the 
cAMP-sensing Epac   in vivo   cAMP reporter assay GFP10-Epac-Rluc3 (  R luc3    =     R luc 
variant with following substitutions: A55T, C124A and M185V) and either RII  β   or 
PKAc. Forty-eight hours aft  er transfection, cells were treated with combinations 
of forskolin (100       μ  M) and SNC80 (1       μ  M), washed twice with PBS, detached with 
PBS plus 5     mM EDTA and resuspended in PBS plus 0.1  %   (w  /  v) glucose. Equal 
amount of cells (100,000 cells per well) were distributed in a   96-well   microtitre 
plate (  Optiplate  ,   PerkinElmer  ,   Life Science  ). Total fl  uorescence and biolumines-
cence were evaluated for each well using a   FlexStation II   (  Molecular Devices  ) 
and   Mithras LB 940   (  Berthold Technologies  ), respectively. uvGFP fl  uorescence 
was excited at 400     nm and read at 515     nm. Fluorescence values were corrected 
by subtracting the autofl  uorescence of cells that do not expressed uvGFP. BRET 
between   R  luc and GFP2 or GFP10 was measured aft  er the addition of 5       μ M   R luc 
substrate   DeepBlueC   ( bisdeoxycoelenterazine ,   PerkinElmer ,   Life  Science ).  BRET 
signals were derived from the emission detected with the energy-acceptor fi  lter 
(515    ±       15     nm; GFP2  /  10) divided by the emission detected with the energy-donor 
fi   lter  (410    ±    40   nm;   R luc /  R luc3).   
  MAPK phosphorylation assay   .       Mammalian cells   .      δ  OR-HEK293 cells were 
grown in 12- or 24-well plate formats. Either 24 or 48     h aft  er splitting or co-
transfection in overexpression studies, confl  uent cells were treated with inhibitors 
(KT5720 for 60     min, pertussis toxin for 16     h), chemical modulators (forskolin, 
6-MBC-cAMP, Sp-5,6-DCl-cBIMPS, Sp-8-PIP-cAMPs, 2-Cl-8-MA-cAMP (all for 
15     min) or Rp-cAMP for 60     min) and  /  or the   δ  OR ligand SNC80 (for 3, 6, 10 or 
15   min).   cAMP  analogues   were  purchased  from   Biolog   (6-MBC-cAMP,   # M012; 
Sp-5,6-DCl-cBIMPS,   # D014;  Sp-8-PIP-cAMPs,   # P005,  2-Cl-8-MA-cAMP,   # C080; 
Rp-cAMP,   #   A002S) 35,36  . Following treatments at 37       °  C, the reactions were 
stopped by direct addition of Laemmli sample buff  er. Equal amount of protein 
were subjected to polyacrylamide gel electrophoresis followed by IB.           Yeast cells   .      
S .   cerevisiae MAT  a   cells (strain BY4741) were grown overnight to saturation 
in complete or appropriate selective medium (for example, synthetic complete 
medium lacking His and Leu). Overnight cultures were used to start fresh 250     ml 
cultures starting at a cell density of 0.05 OD  600   or less and grown to 0.1 OD  600 . 
Cells were stimulated with diff  erent concentrations of     α  -factor   (  Zymo Research  , 
  #  Y1001) for 15     min, and cell lysates were prepared as described previously  33 . 
We used the same   phospho-p44  /  42 MAP kinase antibody     #  9101 (  Cell Signaling 
Technology  ) which cross-reacts with phosphorylated Kss1 or Fus3 MAP kinases 
that are activated by   α -factor.    
  Analysis of yeast morphological phenotypes   .      S. cerevisiae   cells were grown 
overnight in either complete or selective (-His, -Leu) low-fl  uorescence medium to 
make a preculture. From the preculture, fresh 3     ml cultures were started,   beginning 
at 0.05 OD  600   or less cell density and grown at 30       °  C with shaking up to 0.1 OD  600 . 
Cultures were treated with diff  erent concentrations of     α -factor  pheromone  
(  Zymo Research     #  Y1001) and further incubated at 30       °  C with shaking. To avoid 
hetero  geneities from diff  erent stages of the cell cycle,   α  -factor-treated cells were 
incubated for 3 to 4     h before taking the images. For image acquisition by micros-
copy,   96-well optical quality clear bottom plates   (  NUNC  ) were used. Diff  erential 
interference contrast images were acquired on a   Nikon     eclipse TE2000-U inverted 
microscope   connected to a CoolSNAP CCD camera using a   ×  60 diff  erential 
interference contrast H Plan APO oil objective. Numbers of cells showing diff  erent 
morphologies (axial budding, bipolar budding, cell cycle arrest and shmooing) 
were counted by eye following treatment of cells with pheromone   α -factor 33 . 
For each condition, 500 to 700 cells were counted.     
  Bcy1 mutagenesis and mutant analyses   .    Conserved  residues  of  the   ‘ Reggai 
peptide ’   of  human  RII β   (protein sequence accession number: NP_002727) were 
mutated in the sequence of the yeast regulatory subunit   Bcy1   (protein sequence 
accession number: P07278). We mutated aspartic acid (D308) and glutamic acid 
(E317) to alanine (see   Fig. 5b  ). Mutagenesis was carried out using standard site-
directed mutagenesis (  Quikchange Site-Directed Mutagenesis Kit  ;   Stratagene  ) 
following the manufacturer  ’  s instructions. Th  e    S.cerevisiae   expression plasmid p415 
(ADH promoter) bearing mutated   bcy1   (    =    Bcy1 * )  was  transformed  into  the   bcy1  Δ  
MAT  a   strain for analysis of MAPK activation and morphological responses as 
described above  33 . 
 Th  e    R luc  PCA 29   assay and the OyCD PCA  60   is performed as described 
p r e v i o u s l y.                       
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